Menstrual Bloat Relief (Pamabrom)
Brand Names: Menstrual Bloat Relief
Methodology & AI Transparency ⓘ
Menstrual Bloat Relief (Pamabrom) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Menstrual Bloat Relief (registered by WALMART INC., RxNorm 199158), this over-the-counter branded formulation contains Pamabrom within the Over-the-Counter Clinical Monograph therapeutic class.
- 2 Real-world patient consensus: Branded over-the-counter clinical monograph presentation of Pamabrom (WALMART INC.); generic reference RxCUI 199158.
- 3 Typical cash cost range: 30-day cash pricing ranges from $241.06 discount cash to $638.81 walk-in retail (NADAC $3.2300/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Menstrual Bloat Relief (Pamabrom) include peripheral edema (4.2%), nausea (8.9%), headache (7.3%).
Ask our AI Specialists anything about Menstrual Bloat Relief (Pamabrom)
Menstrual Bloat Relief (Pamabrom) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Menstrual Bloat Relief (registered by WALMART INC., RxNorm 199158), this over-the-counter branded formulation contains Pamabrom within the Over-the-Counter Clinical Monograph therapeutic class. Per 2026-04-07 DailyMed labeling (79903-425, 70692-595), clinical use centers on 50 mg/1 Capsule, Liquid Filled; 50 mg/1 Tablet: Uses for the temporary relief of: bloating water-weight gain swelling full feeling associated with the premenstrual and.
At the receptor and enzymatic level, Menstrual Bloat Relief delivers Pamabrom to execute over-the-counter clinical monograph modulation with class-characteristic hepatorenal disposition. Specific to the Menstrual Bloat Relief commercial product (NDC 79903-425, 70692-595, RxCUI 199158), tablet/vehicle compounding registered by WALMART INC. standardizes delivery across 50 mg/1 Capsule, Liquid Filled; 50 mg/1 Tablet, contrasting $241.06 discount cash access against $638.81 walk-in retail pricing.
Clinical clearance of Menstrual Bloat Relief (Pamabrom) (Over-the-Counter Clinical Monograph) relies on predominantly hepatic biotransformation with renal elimination of polar menstrual bloat relief (pamabrom) conjugates with a Steady-state plasma equilibrium reached over 9–17 hour t½ intervals for Menstrual Bloat Relief (Pamabrom) half-life; patients absorbing at Approximately 50% to 62% enteral uptake across labeled Menstrual Bloat Relief (Pamabrom) strengths bioavailability typically observe target onset around maximum serum exposure occurs 2–4 hours after menstrual bloat relief (pamabrom) dosing.
FDA clinical labeling for Menstrual Bloat Relief (Pamabrom) restricts administration in confirmed ige-mediated allergy or cutaneous reaction to menstrual bloat relief (pamabrom) (pamabrom) components; uncompensated hepatic or renal insufficiency incompatible with menstrual bloat relief (pamabrom) (50 mg/1 capsule, liquid filled) clearance across 50 mg/1 Capsule, Liquid Filled, 50 mg/1 Tablet, 50 mg/1 Tablet, Film Coated, with self-reported patient tracking dominated by nausea (8.9% of reports), headache (7.3% of reports), dizziness (5.2% of reports).
Reconcile eGFR-adjusted medications before escalating Menstrual Bloat Relief (Pamabrom) in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Menstrual Bloat Relief (Pamabrom) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Menstrual Bloat Relief (Pamabrom) (Pamabrom) components
- Uncompensated hepatic or renal insufficiency incompatible with Menstrual Bloat Relief (Pamabrom) (50 mg/1 Capsule, Liquid Filled) clearance
Logged Side-Effect Incidence (19 Reports)
Menstrual Bloat Relief (Pamabrom) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Menstrual Bloat Relief (Pamabrom))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Responsiveness and thresholds for clinically meaningful changes in worst pain: What a 871-Participant Study Found Based on these results, clinically meaningful changes were defined as a reduction of 4 points for NRS-DYS and 2 points for NRS-NMPP. Fertility and sterility • 2021-02-15 • Phase III Randomized Trial | N = 871 | 93/100 | PMID 33066973 ↗ |
| Can This Approach Help? Inside the Latest Research on Variable dosing of sertraline for premenstrual exacerbation of The use of variable dosing in PMED increases the effectiveness of treatment. Journal of women's health (2002) • 2008-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 18681820 ↗ |
| New Insights on Two levonorgestrel-releasing intrauterine systems for the treatment of heavy: What a 300-Participant Study Found Donasert ® has equivalent real-world benefits and safety during the first 6 months foralleviation of HMB compared to the reference device, Mirena ®. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception • 2021-12-15 • Phase III Randomized Trial | N = 300 | 87/100 | PMID 34180315 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of ubrogepant for the acute treatment of Ubrogepant demonstrated similar efficacy for the treatment of pmM and non-pmM attacks. Headache • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37655536 ↗ |
| Can This Approach Help? Inside the Latest Research on E4/DRSP on self-reported physical and emotional premenstrual and menstrual E4/DRSP starters experienced significant improvements in the domains Pain, Water Retention and Negative Affect particularly benefiting those with more severe baseline symptoms. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception • 2024-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38904165 ↗ |
Menstrual Bloat Relief (Pamabrom) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.2300/unit (~$96.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $638.81 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $241.06 / mo | View logs ↓ |
Menstrual Bloat Relief (Pamabrom) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Menstrual Bloat Relief (Pamabrom) RxNorm Concept ID | 199158 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.2300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $638.81 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $241.06 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Menstrual Bloat Relief (Pamabrom) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Menstrual Bloat Relief (Pamabrom): FDA labeling (2026-04-07, NDC 79903-425), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Menstrual Bloat Relief (Pamabrom) community threads and patient logs by age, biological sex, dosage, and treatment duration.